

**SUBMISSION COVER SHEET**

**IMPORTANT:** Check box if Confidential Treatment is requested

**Registered Entity Identifier Code (optional): 21-184**

**Organization: Chicago Mercantile Exchange Inc. ("CME")**

**Filing as a:**  DCM  SEF  DCO  SDR

**Please note - only ONE choice allowed.**

**Filing Date (mm/dd/yy): June 8, 2021 Filing Description: Notification to the Commission that its New York Data Center will migrate to New Jersey**

**SPECIFY FILING TYPE**

**Please note only ONE choice allowed per Submission.**

**Organization Rules and Rule Amendments**

- Certification § 40.6(a)
- Approval § 40.5(a)
- Notification § 40.6(d)
- Advance Notice of SIDCO Rule Change § 40.10(a)
- SIDCO Emergency Rule Change § 40.10(h)

**Rule Numbers:** N/A

**New Product**

**Please note only ONE product per Submission.**

- Certification § 40.2(a)
- Certification Security Futures § 41.23(a)
- Certification Swap Class § 40.2(d)
- Approval § 40.3(a)
- Approval Security Futures § 41.23(b)
- Novel Derivative Product Notification § 40.12(a)
- Swap Submission § 39.5

**Product Terms and Conditions (product related Rules and Rule Amendments)**

- Certification § 40.6(a)
- Certification Made Available to Trade Determination § 40.6(a)
- Certification Security Futures § 41.24(a)
- Delisting (No Open Interest) § 40.6(a)
- Approval § 40.5(a)
- Approval Made Available to Trade Determination § 40.5(a)
- Approval Security Futures § 41.24(c)
- Approval Amendments to enumerated agricultural products § 40.4(a), § 40.5(a)
- "Non-Material Agricultural Rule Change" § 40.4(b)(5)
- Notification § 40.6(d)

**Official Name(s) of Product(s) Affected:**

**Rule Numbers:**



Christopher Bowen  
Managing Director and Chief Regulatory Counsel  
Legal Department

June 8, 2021

**VIA E-MAIL**

Christopher J. Kirkpatrick  
Office of the Secretariat  
Commodity Futures Trading Commission  
Three Lafayette Centre  
1155 21st Street, N.W.  
Washington, DC 20581

**RE: CFTC Regulation 40.10(a) Advance Notice - Chicago Mercantile Exchange Inc.'s Notification to the Commission that its New York Data Center will migrate to New Jersey. CME Submission No. 21-184**

Dear Mr. Kirkpatrick:

Chicago Mercantile Exchange Inc. ("CME"), pursuant to Commodity Futures Trading Commission (the "Commission") Regulation 40.10, submits this advance notice that CME will migrate from its New York Data Center ("Vesey") to New Jersey datacenter located in New Jersey, as its primary backup data center, with an anticipated go-live date of August 8, 2021. CME is providing notice the Commission of the material change to its operation, there is no correlating rule change to this operational change.

The purposes of the notification regarding the change in data center is to alert the Commission that New York data center, currently operating as the primary backup data center, will migrate to a data center located in New Jersey. This data center will be an "all disaster recovery data center" housing the primary back-up for electronic trading, clearing, and regulatory infrastructures.

CME reviewed the designated clearing organization core principles ("Core Principles") as set forth in the Commodity Exchange Act ("CEA"). During the review, CME identified the following Core Principles as potentially being impacted:

- System Safeguards: CME has identified risks associated with the migration and will implement measures to mitigate such risks. This migration allows CME to maintain its robust business continuity program and the reliability and security of its backup facilities.

CME certifies that the proposed migration complies with the CEA and the regulations thereunder. There were no substantive opposing views to this action.

Notice of this submission has been concurrently posted on CME Group's website at <http://www.cmegroup.com/tools-information/advisorySearch.html#category=Clearing&topic=alltopics>.

If you require any additional information regarding this submission, please contact the undersigned or Tim Maher at (312) 790-2730 or [timothy.maher@cmegroup.com](mailto:timothy.maher@cmegroup.com). Please reference our CME Submission No. 21-184 in any related correspondence.

Sincerely,

/s/ Christopher Bowen  
Managing Director and Chief Regulatory Counsel